SCHEMBL7149659

SCHEMBL7149659

Cc1cccc(NS(=O)(=O)CCSc2nc3ccccc3s2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
HSD17B10 Q99714 2/20 0.59
MAPT P10636 7/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
KMT2A Q03164 3/20 0.55
LMNA P02545 3/20 0.55
HTT P42858 2/20 0.55
CYP1A2 P05177 4/20 0.51
CYP2D6 P10635 3/20 0.51
CYP2C19 P33261 3/20 0.51
IDO1 P14902 1/20 0.51
CYP3A4 P08684 3/20 0.50
CYP2C9 P11712 2/20 0.50
MEN1 O00255 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
STAT6 P42226 1/20 0.50
HTR1A P08908 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7147570 0.94 ALDH1A1 (0.54) ALDH1A1HSD17B10MAPTSMN1; SMN2KMT2A
SCHEMBL7149819 0.93 ALDH1A1 (0.53) ALDH1A1HSD17B10MAPTSMN1; SMN2KMT2A
SCHEMBL7146699 0.91 ALDH1A1 (0.47) ALDH1A1HSD17B10MAPTSMN1; SMN2KMT2A
SCHEMBL7154107 0.89 MAPT (0.52) ALDH1A1HSD17B10MAPTSMN1; SMN2KMT2A
SCHEMBL7150889 0.88 ALDH1A1 (0.62) ALDH1A1HSD17B10MAPTSMN1; SMN2KMT2A
SCHEMBL7151736 0.86 ALDH1A1 (0.56) ALDH1A1HSD17B10MAPTSMN1; SMN2KMT2A
SCHEMBL7153219 0.86 PDK1 (0.47) ALDH1A1MAPTSMN1; SMN2KMT2ALMNA
SCHEMBL7146167 0.85 ALDH1A1 (0.43) ALDH1A1HSD17B10MAPTSMN1; SMN2KMT2A
SCHEMBL7148116 0.84 ALDH1A1 (0.42) ALDH1A1HSD17B10MAPTSMN1; SMN2KMT2A
SCHEMBL7151763 0.83 POLB (0.42) ALDH1A1HSD17B10MAPTSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 ALDH1A1 2919/4885HSD17B10 2088/4885MAPT 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.